0000749647 false 0000749647 2023-06-14 2023-06-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 14, 2023 (June 14, 2023)

 

IMUNON, INC.

(Exact name of registrant as specified in its Charter)

 

Delaware   001-15911   52-1256615

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

997 Lenox Drive, Suite 100, Lawrenceville, NJ   08648-2311
(Address of principal executive offices)   (Zip Code)

 

(609) 896-9100

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered

Common stock, par value $0.01 per share

   IMNN   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On June 14, 2023, Augustine Chow, Ph.D., a Class I member of the Board of Directors (the “Board”) of Imunon, Inc. (the “Registrant”), retired from the Registrant’s Board upon conclusion of the 2023 Annual Meeting of Stockholders (the “Meeting”). Dr. Chow has served on the Registrant’s Board since March 2007 and was a member of the Board’s Compensation and Audit Committees. Dr. Chow’s current term as a Class I Board member was scheduled to end as of the Meeting. With Dr. Chow reaching 70 years of age in 2023 and having served on the Board for 16 years, the Registrant chose not to include Dr. Chow in its slate of nominees for re-election at the Meeting. Dr. Chow’s retirement from the Board was not because of any disagreement with management or the Board relating to the Registrant’s operations, policies or practices.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMUNON, INC.
     
Dated: June 14, 2023 By: /s/ Jeffrey W. Church
    Jeffrey W. Church
    Executive Vice President and Chief Financial Officer

 

 

Celsion (NASDAQ:CLSN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Celsion Charts.
Celsion (NASDAQ:CLSN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Celsion Charts.